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CME ARTICLE
Spiradenocarcinoma: A Comprehensive Data Review
Roxane D. Staiger, MD,* Birgit Helmchen, MD,† Claudia Papet, MD,‡ Diana Mattiello, MD,§
and Urs Zingg, MD¶
Introduction: Spiradenocarcinomas (SCs) are rare and potentially
aggressive skin adnexal tumors. Optimal treatment has not yet been
established. Experiences with this carcinoma are mostly presented in
case reports and few case series.
Objective: To generate to a synopsis of published data on SC with
regard to diagnostic procedures, treatment, and outcome.
Results: Median patient age was 60 years and sex distribution was
balanced. Tumor manifestations were evenly distributed within the
sweat gland carrying skin. The most commonly reported symptom was
accelerated growth of a longstanding indolent lesion, typically present
for more than 2 years. Metastatic spread to the lung, bone, lymph nodes,
liver, kidney, and breast has been documented. For staging computed
tomography (CT) and positron emission tomography-CT are recom-
mended, especially for detection of hematogenic metastases and lymph
node involvement. Clear resection margins and tumor free regional
lymph nodes reduce recurrence and carcinoma related death. Although
low-grade SCs were reported over 3 times more often, high-grade
carcinomas show a greater likelihood for recurrence and lethal outcome.
Conclusion: Suspicion of an SC should lead to performance of
a magnetic resonance imaging for deﬁning tumor extent, and
a ﬂudeoxyglucose positron emission tomography-CT for detection
of metastases. Radical tumor excision and resection of tumor
involved regional lymph nodes are essential for a curative approach.
Histopathological evaluation should involve determination of tumor
differentiation grade, because high-grade carcinomas seem to have
a much more aggressive behavior. Excision of distant metastases has
no therapeutic value. Follow-up needs to be carried out in short
intervals with frequent imaging.
Key Words: spiradenocarcinoma, malignant spiradenoma, sweat
gland tumor, skin adnexal tumor, review
(Am J Dermatopathol 2017;39:715–725)
LEARNING OBJECTIVES
Spiradenocarcinomas are rare and potentially aggres-
sive adnexal neoplasms evolving from benign spiradenomas.
Due to their scarcity guidelines for the optimal treatment of
these cancers have not been determined so far. This CME
article is intended to call attention to the clinical presentation
and pathological and immunehistological features of spirade-
nocarcinomas; it also provides recommendations for their
diagnostics, treatment, and follow-up.
After participating in this CME activity participants
should be able to:
1. Explain the role and application of medical imaging,
surgical resection, adjuvant treatments, and follow-up for
treatment of spiradenocarcinomas.
2. Describe the main histopathological and immunehisto-
chemical features of spiradenocarcinoma for diagnostics
and prognostics.
3. Name possible preventive measures.
INTRODUCTION
Spiradenocarcinomas (SCs), also referred to as malignant
eccrine spiradenomas,1–3 are rare malignant adnexal neoplasms
arising from a benign spiradenoma of the eccrine sweat gland.1
They are presumed to be highly aggressive. However, in the
recent literature a more favorable clinical course in cases with
low-grade histomorphological features has been reported.4–6
The eccrine spiradenoma is considered the primary skin lesion
from which an SC evolves, but de novo appearances have been
reported as well.7–9 Accelerated growth of a long-standing
lesion, pain, and ulceration are the most common symptoms
that lead to referral. Bluish discoloration and impairment re-
sulting from tumor growth have also been described.3,10–12 A
connection to the Brooke–Spiegler Syndrome, an autosomal
dominant genetic disorder, phenotypically characterized by
multiple skin tumors, such as spiradenomas, cylindromas, tri-
choepitheliomas, and tumors of the parotid gland, is sus-
pected.13–15 The tumor suppressor gene CYLD, located on
chromosome 16q12-q13 has been identiﬁed by genetic studies
to encode for hereditary transmission of multiple familiar cy-
lindromas as well as its associated tumors arising from skin
appendices and the parotid gland.16–18
One hundred twenty cases of SC have been published
up to December 2015, most of them as case reports. Because
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of its rarity the optimal treatment for SC is unclear. Our own
difﬁculties with a patient with SC and the absence of
guidelines for treatment have led to the objective to
summarize the published data to ﬁnd some guidance for
diagnosis, treatment, and follow-up of SCs.
LITERATURE REVIEW
Materials and Methods
PubMed was searched for the key words “spiradeno-
carcinoma” (All Fields) and “malignant spiradenoma” (All
Fields) up to December 31, 2015. This led to 151 matching
results: 34 cases with the key word “spiradenocarcinoma”
and 117 with “malignant spiradenoma.” Included in this
review were reports with a histopathological diagnosis of
SC, malignant spiradenoma, or with malignant differentia-
tion of a spiradenoma. Reports of tumors consisting of
a combination of different skin adnexal carcinomas (21),
duplicate reports (11), and studies in which data concerning
SCs could not be distinguished from other skin adnexal
tumors (7) were excluded. One hundred twenty patients
were presented in 71 case reports3,6–12,15–50,51–80 and 3 case
series.5,14,81 Each case report was analyzed for patient’s age,
sex, and ethnicity. Tumor characteristics were collected
regarding size, location and duration of presence, symptoms
as well as their existence until presentation. We extracted
clinical data concerning treatment, staging, and histopatho-
logical features including immunehistochemical proﬁle if
available. Further, information on the clinical course, such
as tumor recurrence, location of recurrence, time span
between primary tumor and recurrence as well as its thera-
peutic approach was gathered. We added our own case to the
analysis (Table 1).
RESULTS
Epidemiology and Clinical Findings
The epidemiology and clinical details of the published
data is presented in Table 2. The median patient age was
60 years (range 8–92 years). SC occurred in 58 women
(47.9%) to 44 men (36.3%). The ethnicity of the patient
was rarely documented (17.3%). Tumor localization was
equally distributed throughout the sweat gland carrying
skin. The median tumor size at presentation was 3 cm
(range 0.8–25 cm). Duration of presence of a previous
lesion ranged from 2 months to 80 years (median 6.5 years).
The most common tumor symptoms were growth accelera-
tion, pain, and ulceration. Bluish discolorations and bleed-
ing ulcers were also mentioned. In 5 cases the tumor mass
caused impairment (ataxia, palsy, hearing loss, ptosis, or
lymph edema) because of its size.8,11,12,19,55 Duration of
symptoms ranged from 1 week to 4 years (median 4
months).
Diagnostics and Staging
Overall, diagnostic procedures and staging were
poorly documented. The ﬁnal diagnosis was based on the
histopathological examination of an excisional biopsy or
surgical resection specimen. Imaging procedures, including
computed tomography (CT) scan (15/121), magnetic reso-
nance imaging (MRI) (9/121), positron emission
tomography-CT(PET-CT) (6/121), chest x-ray (4/121) and
ultrasound (4/121), and scintigraphy of the lymphatic
drainage (2/121) area were used for staging. Furthermore,
one patient received a mammography, because of the tumor
biopsy’s histological pattern’s similarity to mammary gland
tissue.
TABLE 1. Case Report SC, Limmattal Hospital, Zurich-
Schlieren, Switzerland
Case Report
Patient
44 year old female, white
Tumor
Upper back
Small lesion present since 15 yrs
50 · 80 · 40 mm
Clinical ﬁndings
Duration of symptoms: 1 mo
Fast growing
Ulceration
Bluish discoloration
Preoperative examinations
Biopsy
MRI
Sonography breasts/axillary region
Mammography
PET/CT 320 MBq18 F-FDG
Therapy
Radical tumor excision (10 mm margin)
Bilateral axillary lymphnodectomy level I and II
Pathological features
Poorly differentiated spiradenocarcinoma, vascular invasion
Surgical margins tumor free
TNM classiﬁcation pT2, V1, G3, R1.
Small basophil cells with an isomorph nucleus, few mitotic ﬁgures
Tubulo-glandular and hyalinized eosinophil stroma
Immunehistochemical features
CK 5/6, 7: positive (weak)
EMA: positive
p63 and p40 antibodies: positive (few)
Expression of estrogen receptor: 10% of tumor cells (weak)
C-KIT: positive; KIT mutation analysis: negative.
TP53: pR273C mutation: 34%
Follow-Up
15 Mt. (death)
Recurrence and therapy
5 Mt. post initial surgery: 5 mm nodule upper lobe right lung
/Wedge resection
12 Mt. pleural tumor mass growth through anterior right thorax wall into
right mammary with rib arrosion
/Palliative chemotherapy: Imatinib
/Palliative radiotherapy of the bone metastases
CK, cytokeratin; C-KIT, tyrosine-protein kinase; EMA, epithelial membrane
antigen; F-FDG, ﬂudeoxyglucose; MBq, megabecquerel; TP53, tumor protein p53.
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Pathologic and Immunohistochemical
Findings
Table 3 presents the pathological data. Tumor grading
was reported in 30% (36/121) of all cases. As histopathologic
criteria for such classiﬁcation antigen KI-67 staining was re-
ported in 58.3% (21 cases), mitotic rate in 36.1% (13 cases),
and no statement was made in 5.5% (2 cases). Tumor grade
was high in 19% (4/21) of cases with tumor recurrence and in
23% (3/13) of the patients who died during follow-up. Further-
more, a wide range of different immunehistochemical markers
was tested. SCs are positive for most cytokeratins with CK 5–7
most frequently being reported. Also tumor protein p53 was
found positive in 90% (28/31); estrogen receptors were rarely
screened for with 63% being negative (5/8).
Treatment
Tumor resection was the primary treatment for all
patients; too advanced tumor progression for complete surgical
resection was the only exception. Surgical excision of the
afﬂicted lymphatic nodes was performed in 83% (10/12), in
patients with extensive tumor spread a lymphnodectomy was
refrained from. In addition to tumor resection, further treatment
was described in 6 case reports. Three patients received
adjuvant radiotherapy,10,20,66 one of them in combination with
chemotherapy.62 For the ﬁrst patient no follow-up or outcome
after radiotherapy was described.10 For the second patient, a 6
months recurrent free survival after radiotherapy (dosage
unknown) was reported.20 In the third case a total dosage of
59.4 Gray (Gy) over 64 days onto the tumor bed was applied
and 45 Gy over 35 days onto the inguinal and pelvic nodes.
Tumor recurrence at the primary tumor location without distant
metastases occurred 9 months later. Despite a wide tumor exci-
sion with lymphadenectomy and hyperthermic isolated limb
perfusion chemotherapy lung metastases occurred 3 months
later; the patient died 20 months after initial diagnosis.66
Four patients underwent adjuvant chemotherapy. The
agents used were 5-FU,66 Tamoxifen3 Epirubicin,7 and Ifos-
famide.7 The fourth patient was already under chemotherapy
treatment because of an adenocarcinoma of the colon with
liver metastases.70 All patients were diagnosed with distant
metastases or died within 4 months. The exception was,
a patient treated with a continuous Tamoxifen therapy after
tumor resection and lymphnodectomy of an estrogen receptor
positive SC of the upper arm. No tumor recurrence was found
after 41 months of follow-up.3
TABLE 2. Summary of Epidemiological and Clinical Information
Epidemiological and
Clinical Information
Total Cases
Available Data
(% of Total Cases)
Recurrence-Free
Survival
(% of Total Cases)
Recurrence
(% of Total Cases)
Death
(% of Total Cases)
Total cases 121 (100) 45 (37.2) 21 (17.4) 13 (10.2)
Age (Median), yrs 60 (8–92) 63 (21–92) 59.5 (30–72) 70 (44–89)
Sex 102/121 (84.3) 43 (42.2) 18 (17.6) 12 (11.8)
Female 58/102 (56.9) 20 (35.5) 12 (20.7) 5 (8.6)
Male 44/102 (43.1) 23 (52.3) 6 (13.6) 7 (15.9)
Ethnicity, n (%) 21/121 (17.4) 8 (38.1) 5 (23.8) 3 (14.3)
White 12/21 (57.1) 6 (50.0) 2 (16.7) 2 (16.7)
African/African American 4/21 (19.0) 0 (0) 2 (50.0) 1 (25.0)
Asian 3/21 (14.3) 2 (66.7) 1 (33.3) 0 (0.0)
Indian 2/21 (9.5) 0 (0.0) 0 (0.0) 0 (0.0)
Tumor location 106/121 (87.6) 43 (60.6) 19 (17.9) 12 (11.3)
Head (face, scalp, neck) 39/106 (36.8) 13 (33.3) 8 (20.5) 8 (20.5)
Trunk (chest, back, abdomen, pelvis) 29/106 (27.4) 12 (41.4) 4 (13.8) 1 (3.4)
Extremities (incl. hand, foot) 38/106 (35.9) 18 (47.4) 5 (13.2) 1 (2.6)
Side of the body 41/121 (33.9) 22 (53.7) 6 (14.6) 1 (2.4)
Left 19/41 (46.3) 10 (52.6) 2 (10.5) 0 (0.0)
Right 22/41 (53.7) 12 (54.5) 4 (18.2) 1 (4.5)
Tumor size (Median), cm 3 (0.8–25) 3 (0.8–25) 4 (0.8–12) 5.5 (1–10)
Time lesion present before symptoms, yrs 0.17–80 8 (0.17–80) 9 (2–50) 4 (0.17–15)
#2 20/66 (30.3) 9 (45.0) 1 (5.0) 2 (10.0)
.2 46/66 (69.7) 18 (39.1) 9 (19.6) 3 (6.5)
Symptoms 64/121 (52.9) 28 (43.8) 23 (35.9) 10 (15.6)
Growth 60/64 (93.8) 24 (40.0) 13 (21.7) 6 (10.0)
Pain 15/64 (23.4) 7 (46.7) 5 (33.3) 0 (0.0)
Ulceration 13/64 (20.3) 6 (46.2) 2 (15.4) 2 (15.4)
Bluish discoloration 4/64 (6.3) 1 (25.0) 1 (25.0) 0 (0.0)
Bleeding 4/64 (6.3) 2 (50.0) 1 (25.0) 1 (25.0)
Disabilities 5/64 (7.8) 1 (20.0) 1 (20.0) 1 (20.0)
Duration of symptoms 0.25 mo–4 yrs 8 mo (0.25 mo–4 yrs) 1 mo (1–23 mo) 2 mo (1–4 mo)
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Outcome
Oncological outcome is shown in Table 4. With
a median follow-up time of 24 months, the total recurrent free
survival was 37% (45/121), cases with tumor recurrence were
reported in 17% (21/121), and the documented occurrence of
death in 10% (13/121). The nodal status and local recurrence
was rarely described. From the reported data, the median of
12 months follow-up time until tumor recurrence (range 1
month–7 years) was calculated. Those patients had tumor
free resection margins in 67% (6/9); of the ones who died
during follow-up R0 resection was described in 40% (2/5).
Lung, bone, and lymph nodes were the most frequently re-
ported locations of metastatic spread. Few cases of liver-,
kidney-, and breast metastases have also been documented.
Of the 13 deaths during follow-up, 3 patients died shortly
after the surgery (1–8 weeks) and 5 showed tumor recurrence
before death (recurrence 5–84 months).
DISCUSSION
The ﬁrst case of an SC was reported in 1971 by Dabska.30
Because of the low incidence of SC only few case series are
available, each with less than 20 patients.5,14,81 This results in
a great variability of published data and makes a meaningful
statistical analysis of the gathered information impossible.
The epidemiological features of SC are unspeciﬁc. SC
occur predominately in the elderly patient (median age 60 years),
however a wide range in patient age has been reported
throughout the literature (8–92 years).53,72 There is no speciﬁc
sex distribution of SC.8,15,81 Our data summary do not support
the suspicion of a predominance of the tumor localization in the
head, neck, and trunk region that was suggested in previous
reports.14,66,81 The large sized carcinomas’ (.10 cm) main symp-
tom was painless growth; therefore, medical consultation may
have been delayed, allowing the tumor to reach such an extent.
A lesion was often present for many years, before rapid growth,
sometimes in combination with pain, ulceration, or less common,
bleeding or discoloration occurred.14,15,44 Therefore, we recom-
mend the preventive excision of every diagnosed spiradenoma.
Preoperative investigations were rarely documented and
consisted mostly of CT scans or MRI for determination of the
extent of tumor inﬁltration. The few authors who added a PET/
CT scan to their staging procedure3,10,28,53,60 describe a notable
gain of valuable information regarding the presence and loca-
tion of metastases, especially if clinical ﬁndings were unre-
markable. Fludeoxyglucose (FDG) PET/CT imaging is
known to have high sensitivity for detection of metastases of
skin tumors,82,83 particularly for primary apocrine sweat gland
carcinomas and eccrine porocarcinomas.84,85 The proportion of
FDG sensitive SC is unknown.
Not only was the follow-up period mostly brief, also
further treatments and course of illness were barely reported
once a recurrence occurred. Speciﬁc tumor markers have not
been identiﬁed yet. The impact of tumor free resection margins
regarding tumor recurrence or survival is unclear.2,66,81 Our
data, however, show fewer recurrences and deaths after tumor
TABLE 3. Summary of Reported Pathologic and Immunehistochemical Findings
Pathologic and
Immunehistochemical Findings
Total Cases
Available Data
(% of Total Cases)
Recurrence-Free
Survival
(% of Total Cases)
Recurrence
(% of Total Cases)
Death
(% of Total Cases)
Total cases 121 (100) 45 (37.2) 21 (17.4) 13 (10.2)
SC grading 36/121 (29.8)
High 8/36 (22.2) 2 (25.0) 4 (50.0) 3 (37.5)
Low 28/36 (77.8) 21 (75.0) 4 (14.3) 4 (14.3)
Cytokeratins
Positive 13/121 (10.7) 7 (53.8) 5 (38.5) 3 (23.1)
CK 5 3/121 (2.5) 2 (66.75) 1 (33.3) 1 (33.3)
CK 6 2/121 (1.7) 1 (50.0) 1 (50.0) 1 (50.0)
CK 7 7/121 (5.8) 3 (42.9) 4 (57.1) 3 (42.9)
Cytokeratin antibodies
AE1 5/121 (4.1) 4 (80.0) 1 (20.0) 0 (0.0)
AE3 5/121 (4.1) 4 (80.0) 1 (20.0) 0 (0.0)
CAM 5.2 3/121 (2.5) 2 (66.75) 1 (33.3) 0 (0.0)
Proteins
p53 28/121 (23.1) 23 (82.1) 2 (7.1) 4 (14.3)
Receptors
Estrogen receptors 3/121 (2.5) 2 (66.75) 1 (33.3) 1 (33.3)
Progesterone receptor 1/121 (0.8) 1 (100) 0 (0.0) 0 (0.0)
Others
MYB 2/121 (1.7) 1 (50) 0 (0.0) 1 (50.0)
c-KIT 1/121 (0.8) 0 (0) 1 (100) 1 (100)
EMA 13/121 (10.7) 10 (76.9) 2 (15.4) 2 (15.4)
c-KIT, tyrosine-protein kinase kit; EMA, epithelial membrane antigen.
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resection with tumor free margins compared with R1 resections
(recurrence 23% vs. 43%), (death 8% vs. 43%). Regional
lymph node excision has been recommended for tumor
positive regional lymph nodes2,3 and sentinel node biopsy is
considered useful in clinically unsuspicious ones.2 However,
the beneﬁt of routine locoregional lymph node dissection is
unknown and therefore not advised.66,81 Our recommendation
for radiological SC diagnostics and staging include MRI for
deﬁning the tumor extent and FDG PET/CT for the detection
of metastases. For treatment, we strongly advice to obtain
tumor free resection margins and recommend the resection of
tumor positive lymph nodes. Follow-up should include recur-
rent imaging; frequency may be broadened over time.
Per deﬁnition, for the diagnosis of an SC areas of
benign spiradenoma must be found adjacent to the malign
transformation in the pathological examinations1 (Fig. 1). The
current WHO classiﬁcation describes 2 major histologic pat-
terns; one shows a continuous transformation from benign to
malignant neoplasm, in the other the malignant transitions are
adjacent to the spiradenoma without structural or cytological
changes1 (Fig. 2). De novo appearances of SC have been
described7–9; they are an explicit rarity, because the malignant
degeneration would need to be concurrent with the primary
growth of the spiradenoma. Further, an interrelation between
spiradenoma, cylindroma, and spiradenocylindroma has also
been reported.4,86 In the 2009, published case series on
adnexal skin tumors,4 4 histomorphological patterns and their
correlation with clinical behavior and prognosis were
described: salivary gland type basal cell adenocarcinoma-
like pattern low-grade (BCAC), salivary gland type BCAC
high-grade, invasive adenocarcinoma not otherwise speciﬁed,
and sarcomatoid (metaplastic) carcinoma. Considering the
long-term-survival rates of 50% for skin adnexal tumors with
TABLE 4. Outcome Summary
Outcome
Total Cases
Available Data
(% of Total Cases)
Recurrence-Free
Survival
(% of Total Cases)
Recurrence
(% of Total Cases)
Death
(% of Total Cases)
Total cases 121 (100) 45 (37.2) 21 (17.4) 13 (10.2)
Follow-up time (Median), mo 24 24 10 15
Resection margins 33/121 (27.3)
R0 resection 26/33 (78.8) 18 (69.2) 6 (23.1) 2 (7.7)
R1 resection 7/33 (21.2) 1 (14.3) 3 (42.9) 3 (42.9)
Lymph node status 26/121 (21.5)
Positive lymph nodes 13/26 (50) 7 (53.8) 4 (30.8) 2 (15.4)
Negative lymph nodes 13/26 (50) 11 (84.6) 2 (15.4) 0 (0.0)
Metastatic spread 23/121 (19.0)
Lung 8/23 (34.8)
Bone 6/23 (26.1)
Lymphatic drainage 5/23 (21.7)
Liver 2/23 (8.7)
Kidney 1/23 (4.3)
Breast 1/23 (4.3)
Recurrence location 21/121 (17.3)
Tumor bed 5/21 (23.8)
Other location 11/21 (52.4)
Death 13/121 (10.7)
w/recurrence 5/13 (38.5)
w/o recurrence 8/13 (61.5)
R0 resection, tumor free resection margins; R1 resection, tumor reaches resection margins; w/, with; w/o, without.
FIGURE 1. Overview: Squamous cell epithelial layer, sub-
epithelial area with high-grade SC, underneath a defined zone
with features of a spiradenoma. Case of an SC of a 44-year-old
white woman, Limmattal Hospital, Zurich-Schlieren, Switzer-
land (Table 1).
Am J Dermatopathol  Volume 39, Number 10, October 2017 SC: A Comprehensive Data Review
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. www.amjdermatopathology.com | 719
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
the histomorphological pattern of BCAC high-grade reported
in this study, these neoplasms seem to be more aggressive
compared with the BCAC low-grade type (100% long-term
survival).4,14 Also invasive adenocarcinoma not otherwise
speciﬁed carcinomas are considered highly malignant neo-
plasms with rather poor outcomes, whereas sarcomatoid car-
cinomas show a relatively good survival.4 However, this
histopathologic classiﬁcation for skin adnexal tumors is not
commonly used yet.
Only in 30% of the published SC cases a tumor grade is
declared; most of them being low-grade carcinomas (28 vs. 8
cases). Corresponding with previous ﬁndings, our data show
a higher incidence regarding tumor recurrence and death in high-
grade carcinomas (recurrence 50% vs. 14%, death 38% vs. 14%)
compared with reported low-grade SC (Table 3).4,5,14 Some SC
feature spindle cells, giving a sarcomatid appearance to the neo-
plasm 4; however, mostly these tumors lack distinctive morpho-
logical features and hold no speciﬁc immunological proﬁle. SCs
are positive for most cytokeratins; also estrogen and progester-
one receptor expression are occasionally found, presumably
because of the common embryologic origin of eccrine sweat
glands and mammary gland tissue.9 Mutations in the TP53 gene
is a known indicator for malignant transformation,87 however,
there is no obvious correlation between the TP53 mutation status
and the p53 tumor suppressor protein expression.88 Although
strong p53 expression has been reported for SC,87 these tumors
typically lack mutations in the TP53 gene.5 Furthermore, immu-
nohistochemical staining for p53 appears to be heterogeneous;
therefore, it cannot be reliably applied for identiﬁcation of malig-
nant transformed areas.5,88 One recent case series analyzed 19
SC cases for myeloblastosis protein (MYB),5 a proto-oncogene
protein that plays an important role in proliferation, apoptosis,
and differentiation of cells.89 Although detected in spiradeno-
mas, MYB is absent in its malign transformation, regardless if
high or low grade. Therefore it may serve as an additional
immunehistochemical marker for the distinction between spira-
denoma and its low-grade malignant transformation.5,90 Our
recommendations for pathologic evaluations of a suspected SC
are ﬁrst, the veriﬁcation of SC according to the 2 major histo-
logic patterns,1 second, the determination of the tumor differen-
tiation grade for a more accurate estimation of the patient’s
prognosis and third, MYB staining for determination of malig-
nant differentiation of a spiradenoma by histomorphologic
uncertainty.
No data on the optimal management strategy concerning
distant metastases or on a satisfactory response of radiotherapy
or chemotherapy has been published.3,14,41,53 There are known
cases of adenoid cystic carcinomas, a type of malign sweat
gland tumor, responding to chemotherapy with Imatinib.91,92
This protein kinase inhibitor targets c-KIT, which is expressed
in a variety of malignant tumors, such as gastrointestinal stro-
mal tumor, malignant melanoma or adenoid cystic carcinoma
of the salivary gland.86,93 A recent study further investigated
benign and malignant sweat gland tumors according to their c-
KIT expression.86 Although immunehistochemical positivity to
c-KIT was present in most analyzed sweat gland tumors, only
the adenoid cystic carcinomas showed a population of c-KIT
positive cells big enough for a useful Imatinib therapy.86 Fur-
thermore, Tamoxifen, a selective estrogen receptor modulator,
has been tried as an adjuvant therapy in a case of estrogen
receptor positive SC.3 No tumor recurrence was stated for 41
months.3 Because of the common embryologic tissue origin,9
estrogen receptors may not only be found in mamma carcino-
mas, but also in rare cases of SC.
Radiotherapy of the tumor site has been recommended
in the past36,74,79 but was hardly performed in the literature. A
literature review from 1986 has declared sweat gland tumors
to be radioresistant, consequently little signiﬁcance was
granted to radiotherapy as treatment of such carcinomas.94
Therefore, Tamoxifen therapy for those rare cases of estrogen
receptor positive SC is the only useful recommendation
regarding adjuvant therapy.
CONCLUSION
Inferred from the available data, suspicion of a SC
should lead to performance of an MRI for deﬁning tumor
extent and FDG PET/CT for detection of metastases. The main
pilar of treatment is radical tumor excision and the resection of
tumor involved regional lymph nodes. Histopathological
evaluation should involve determination of tumor differentia-
tion grade for prognosis estimation; high-grade carcinomas
seem to have a much more aggressive behavior compared with
low-grade SC, which carry the potential for cure. To evaluate
the possibility of an adjuvant Tamoxifen therapy, staining for
estrogen receptors is recommended. Excision of distant
metastases has no therapeutic value, but may be done for
symptom alleviation. Follow-up needs to be carried out in short
intervals with frequent imaging. To assess the inﬂuence of each
clinical, radiological, or histopathological parameter regarding
patient’s outcome, a prospective uniform international data
collection would be required.
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After participating in this CME activity participants should be able to explain the role and application of medical
imaging, surgical resection, adjuvant treatments, and follow-up for treatment of spiradenocarcinomas, describe the main
histopathological and immunehistochemical features of spiradenocarcinoma for diagnostics and prognostics, name possible
preventive measures.
1. Which statement regarding surgical treatment of spiradenocarcinomas is true?
a. Resection margin of 1 cm is imperative for prevention of local tumor recurrence
b. R0 resection (tumor free resection margins) is associated with lower tumor recurrence
c. Excision of tumor positive regional lymph nodes has no impact on the course of the disease
d. Resection of distant metastases decelerates disease progress
2. Which statement for diagnostics or nonsurgical treatment of spiradenocarcinomas is true?
a. Tumor staging should include PET/CT for diagnosis of metastases
b. Yearly clinical check ups are the current recommendations for follow-up after surgical resection of spiradenocarcinomas
c. The combination of chemotherapy and radiotherapy is a promising adjuvant therapy
d. Neoadjuvant Tamoxifen therapy increases recurrent free survival rate
3. Which statement of the pathological features of spiradenocarcinomas is true?
a. The histologic pattern of a spiradenocarcinoma always shows a continuous transformation from benign to malignant
neoplasm
b. Spiradenocarcinoma have distinctive morphological features
c. The quantity of atypical mitotic ﬁgures has no inﬂuence on the prognosis
d. Essential for the diagnosis of spiradenocarcinoma a part of benign spiradenoma must be found adjacent to the area of
malign transformation
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4. All of the following pathological or immunehistological ﬁndings can be detected in spiradenocarcinomas. Which of them has
the greatest signiﬁcance for prognostics?
a. p53 tumor suppressor protein expression
b. Mitotic ﬁgure count
c. Presence of estrogen/progesterone receptors
d. MYB staining
5. Which of the following approaches is the most promising preventive measure for spiradenocarcinomas?
a. Frequent clinical follow-up of diagnosed spiradenomas
b. Preventive Tamoxifen therapy
c. Preventive excision of ascertained spiradenomas
d. No preventive measure can be taken
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